jueves, 8 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

The agent security gap: 54% of enterprises have already had an AI agent incident, and most still let agents share credentials

View original at venturebeat.com
VentureBeat AI - Enterprise Ai Title: The agent security gap: 54% of enterprises have already had an AI agent incident, and most still let agents share credentials Date: 2026-07-16 19:02 Source: https://venturebeat.com/ai/the-agent-security-gap-54-of-enterprises-have-already-had-an-ai-agent-incident-and-most-still-let-…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A clear majority (59%) of enterprises intend to adopt a new, additional, or replacement agent security solution within twelve months, and 29% within the next quarter.

    60% confidence
  • Among organizations that have been hit by an incident, 42.1% plan to adopt, add, or replace agent security tooling within 90 days, versus 14.0% of organizations with no incident; after a confirmed incident this rises to 52.6%.

    60% confidence
  • Incident/near-miss rate rises from 49% in mid-market companies (101-1,000 employees) to 63% at larger enterprises (above 1,000 employees), while sandbox isolation falls from 35% to 20% and satisfaction drops from 4.36 to 3.97.

    60% confidence
  • The most common agent security budget allocation is 6-10% (46%), a third of enterprises (34%) spend 5% or less, and only 24% spend more than a tenth.

    60% confidence
  • Only 35% of enterprises believe their AI-enabled defenses are ahead of AI-enabled attackers; 53% rate the balance as even or tilted toward the attacker.

    60% confidence
  • OpenAI's guardrails lead agent security tooling usage at 51%, and 82% of enterprises name a provider-native offering as their single primary security layer.

    60% confidence
  • More than half of organizations (54%) have already experienced a confirmed agent security incident (18%) or a near-miss caught before harm (36%).

    60% confidence
  • Organizations with credential sharing anywhere in the fleet were hit with an incident or near-miss at 63.5% (47 of 74), versus 40.9% (9 of 22) for organizations where every agent has its own scoped identity.

    60% confidence
  • Satisfaction with agent security tooling averages 4.2 out of 5 overall, and 4.1 for value for money.

    60% confidence
  • Twelve percent of respondents include an agent-identity product anywhere in their consideration set, and this figure is essentially unchanged among credential-sharing organizations that have already had an incident.

    60% confidence
  • Only about a third (32%) of enterprises give every agent its own scoped, managed identity; the rest report shared credentials somewhere in the agent fleet.

    60% confidence
  • Only three in ten enterprises (30%) isolate their highest-risk agents in sandboxes.

    60% confidence

Data points we hold from this source

OpenAI · agent security tooling usage rate26 percent
OpenAI · purchase consideration rate34 percent
Anthropic · purchase consideration rate29 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
The agent security gap: 54% of enterprises have already had an AI agent incident, and most still let agents share credentials — Source | Via News | es.VIA.NEWS